newsfilter
← Latest News
GlobeNewswire·

Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in late November 2026Sol-Gel has initiated a proof-of-concept